Skip to main content
. 2022 Jun 14;13:911347. doi: 10.3389/fimmu.2022.911347

Table 5.

AUCs for treatment outcomes at weeks 12 and 24.

Measures AUC for both ACR50 and PASI50 at week 12 AUC for both ACR70 and PASI75 at week 24
AUC (95%CIs) p AUC difference p AUC (95%CIs) p AUC difference p
b-MPO–DNA 0.74 (0.55–0.93) 0.047 Reference 0.88 (0.74–1) 0.009 Reference
b-ESR 0.66 (0.42–0.89) 0.195 0.08 0.60 0.68 (0.47–0.81) 0.224 0.20 0.14
b-CRP 0.72 (0.5–0.94) 0.075 0.02 0.877 0.84 (0.69–0.99) 0.018 0.03 0.76
ΔMPO–DNA 0.92 (0.8–1) 0.004 Reference
ΔESR 0.6 (0.31–0.88) 0.143 0.31 0.036
ΔCRP 0.86 (0.7–1) 0.013 0.05 0.42
ΔMPO–DNA% 0.92 (0.8–1) 0.004 Reference
ΔESR% 0.54 (0.28–0.8) 0.134 0.373 0.02
ΔCRR% 0.73 (0.54–0.92) 0.097 0.182 0.184

Values are presented as areas under curve (95% CIs). Treatment outcomes are referred to the achievement of both ACR50 and PASI50 at week 12 and the achievement of both ACR70 and PASI75 at week 24. Abbreviations: b-MPO–DNA/ESR/CRP, serum MPO–DNA complex/ESR/CRP at baseline; ΔMPO–DNA/ESR/CRP, reduction of serum MPO–DNA/ESR/CRP at 12 weeks in absolute value; ΔMPO–DNA/ESR/CRP%, reduction of serum MPO–DNA/ESR/CRP at 12 weeks in percentage.